CN1762386A - Bone density-increasing and senility-postponing capsule formulation - Google Patents
Bone density-increasing and senility-postponing capsule formulation Download PDFInfo
- Publication number
- CN1762386A CN1762386A CN 200510029989 CN200510029989A CN1762386A CN 1762386 A CN1762386 A CN 1762386A CN 200510029989 CN200510029989 CN 200510029989 CN 200510029989 A CN200510029989 A CN 200510029989A CN 1762386 A CN1762386 A CN 1762386A
- Authority
- CN
- China
- Prior art keywords
- calcium carbonate
- micropowder
- capsule
- bone density
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present pertains to the field of traditional Chinese medicine, more specifically a capsule for increasing compact bone substance density and delaying senescence, which is prepared from soybean isoflavones, shark cartilage micropowder, calcium carbonate, vitamin B6, folic acid and medicinal auxiliary materials.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to a kind of control causes osteoporosis, women's aging, climacteric syndrome because of estrogen deficiency and/or estrogen exhaustion capsule preparations.
Background technology
Estrogen has the physiological function of keeping female sex organ and secondary sexual characteristics, participates in the physiological activity of each tissue system of health.The women steps into the middle age, climacteric, gonad function was failed gradually to old, and the secretion of body inner estrogen reduces even be exhausted, health produces a series of variations and symptom, comprise cryptorrhea, metabolism disorder, cardiovascular system pathological changes, osteoporosis, urinary tract infection, skin aging, senile vaginitis, and climacteric syndrome such as autonomic nervous system disorder, be the able-bodied main root of puzzlement middle aged and aged women.Treat these diseases, the most frequently used and effective method is Hormone Replacement Therapy (HRT), promptly gives low dose of estrogen (mainly being estradiol), prevention and alleviation climacteric syndrome.But clinical practice is found, uses the danger that estrogen may increase carcinoma of endometrium, breast carcinoma generation, and user has a misgiving.Exploitation pure natural plants estrogen mainly is soybean isoflavone, and the symptom of control estrogen deficiency is subjected to showing great attention to of domestic and international medical and health and sociology aspect, is the research focus of field of health care products.
Summary of the invention
The capsule preparations that the purpose of this invention is to provide a kind of bone density improving and deferring senility.Capsule preparations of the present invention can be prevented and treated bone loss, osteoporosis, and women's aging and climacteric syndrome, its health-care effect is good, no toxicity, the quality of life that helps improving middle aged and aged women.
Compound capsule of the present invention by soybean isoflavone wherein isoflavone content in the 35%-43% scope, shark cartilage micropowder, calcium carbonate, vitamin B
6, folic acid adds the medicine adjuvant and makes (trade name: phoenix English capsule).
Described soybean isoflavone is a phytoestrogen, comprise ten surplus kind of chemical compound, its similar is in estrogen, combines with estrogen receptor and plays a role, its intensity is 1 * 10 of estradiol
-3To 1 * 10
-5Doubly, with receptor to combine speed more faster than estrogen, do not have the side effect of steroid hormone, find no carcinogenic probability.Bone and its cells is cultivated and to be shown, soybean isoflavone can be directly by the differentiation of osteoclast before suppressing, or osteoclast is reacted the heavy absorption function of the bone that suppresses osteoclast to parathyroid hormone before suppressing.
The test of removal ovary rat animal model shows, the oral soybean isoflavone 0.712-1.424mmol/kgd of rat, and 25 days, to compare with matched group, mononuclear cell or multinucleated osteoclast increase and reduce, and Histological parameter shows that also bone heavily absorbs decline.
After the menopause or the clinical research result of senile osteoporosis treatment, early stage at natural menopause, give the soybean isoflavone of 600mg/d and the calcium of 1g/d, the matched group list is given calcium, results suggest, soybean isoflavone has the trend that strengthens the lumbar vertebra mineral content, if give a small amount of estrogen (itself can not strengthen the Radial bone density 0.3mg/d estrogen) simultaneously, can significantly strengthen postmenopausal women's bone density.
Menopausal women normal with the bone amount or that lower is an object, divides four groups to give 84mg/d, 126mg/d, placebo and estrogen replacement therapy.Followed the trail of for 24 weeks, measure lumbar vertebra, neck of femur and test front and back, Ward ' s trigonum bone density, the result: soybean isoflavone 84-126mg/d can slow down the menopausal women bone loss, and it is relatively stable to keep bone density, and its produce effects amount is 126mg/d.
Soybean isoflavone is intravital antioxidant, and to antioxidant radical and lipid peroxidation, it also can induce the activity of antioxidase, reduce DNA and cell and sustain damage, and protection cell and organ, thereby play function in delaying senility.In addition, soybean isoflavone is prevented and treated the function of cardiovascular and cerebrovascular disease such as atherosclerosis, hyperlipidemia etc. in addition.
Shark cartilage powder contains more organic calcareous, soybean isoflavone exist with effect under, be absorbed by the body easily.Shark cartilage powder contains abundant polysaccharide, and as mucopolysaccharide, chondroitin sulfate, these polysaccharide can effectively improve immune function of human body, and health invigorating has deferring senility.It also has scavenging action to reactive oxygen free radical, prevents cell inactivation and sudden change, plays delaying senility function.
Calcium carbonate is the calcium source, under the existence and effect of soybean isoflavone, is absorbed by the body easily.
Soybean isoflavone of the present invention is available from North China drugmaker; Described shark cartilage powder is for buying behind the shark cartilage by the known method processing and preparing; All the other supplementary materials are commercial.
Preparation of the present invention is made (daily dose) by the component of following weight proportion:
Soybean isoflavone, 0.15-0.5g
Shark cartilage micropowder 0.3-0.7g
Ground calcium carbonate 0.5-0.8g
Vitamin B
62mg
Folic acid 0.2mg
Micropowder silica gel 2-8mg
Magnesium stearate 1-5mg
Preparation of the present invention is made capsule by following preparation method,
Get each component by above-mentioned weight:
Soybean isoflavone, isoflavone content is in the 35%-43% scope;
Get dry shark pygostyle, selected back chopping, the mill coarse powder is ground into granularity 200 orders-300 order micropowder, sealing, sterilization, the shark cartilage micropowder;
Ground calcium carbonate is made binding agent with sodium carboxymethyl cellulose, makes fine grained;
Above-mentioned three kinds of raw materials are fine powder, are not suitable for the production of capsule loading machine, make fluidizer so add an amount of micropowder silica gel, and magnesium stearate is made antiplastering aid, and ground calcium carbonate is made binding agent with sodium carboxymethyl cellulose, makes fine grained separately.Above-mentioned mixing of materials is even, through the powder mobility-detected, and cloud test, the capsule loading machine is loaded capsule automatically.
Described capsule, every day, dosage was distributed into four capsules, loading amount 360mg/.
Usage and consumption: every day secondary, each two.
Capsule of the present invention can be used as health product and takes for a long time, and can take in soybean isoflavone 80-100mg every day, replenishes calcium amount 200-350mg simultaneously.
Capsule of the present invention has carried out the toxicity detection, and the result shows: free of toxic effects.
1, acute toxicological experiment: LD
50>21.5g/kg body weight;
2, Ames experiment: not seeing has mutagenic action;
3, mouse sperm deformity experiment: not finding has mutagenic action to sexual cell in vivo;
4, mouse bone marrow cells micronucleus test: do not find bone marrow cells in mice is caused the chromosome breakage effect;
5, rat 30 days is fed experiment: to rat ingest, index inspections such as body weight gain, hemoglobin, red blood cell count(RBC), numeration of leukocyte, glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT, blood urea nitrogen, cholesterol, triglyceride, albumin, globulin, glucose, all no abnormal, pathological change is not found in the histopathology check yet.
Rat increases bone density function test result and shows: the bone density improving effect is arranged.
Basic, normal, high three dosage groups are established in experiment: each organizes feedstuff calcic 1500,3000,5000mg/kg respectively, sets up three matched groups simultaneously: basic, normal, high calcium matched group (difference calcic 800,3000,5000mg/kg in the feedstuff).Experimental result shows: each dosage group rat body weight of sample, height and corresponding control rats relatively do not have significant difference; Dot density all is significantly higher than low calcium matched group in the weight of high, middle dosage group femur, femur length, femur metaphysis bone density, the femur.Preparation calcium content of the present invention is 21.8%, and the human body recommended amounts is 1.44g/60kg body weight every day.
The test of animal deferring senility:
Aged mouse-anti oxidimetry result shows: middle dosage group rat blood serum lipid peroxide catabolite malonaldehyde (MDA) content significantly is lower than matched group (P<0.05), and with age group there was no significant difference in March (P>0.05), show that this present invention preparation has stronger reduction lipid peroxidation; Low dose group, middle dosage group and high dose group rat blood serum superoxide dismutase (SOD) vigor show that apparently higher than matched group (P<0.05) preparation of the present invention has the increased SOD effect.
The drosophila survival result of the test shows: female fruit bat of 0.432% concentration group and matched group relatively show to prolong average life 4.5 days that the demonstration of 0.48%, 0.144% and 0.432% concentration group prolongs female fly average life 1.9-4.5 days (P<0.05); 0.016%, male fly of 0.048% and 0.144% concentration group and matched group relatively show to prolong average maximum life span 6.2-8.6 days (P<0.05).The result shows: preparation of the present invention has delaying senility function.
The specific embodiment
Embodiment 1
Take by weighing raw material (daily dose) by following weight proportion
The soybean isoflavone of isoflavone content 35%, 0.15g
Shark cartilage micropowder 0.3g
Ground calcium carbonate 0.8g
Vitamin B
62mg
Folic acid 0.2mg
Micropowder silica gel 2mg
Magnesium stearate 1mg
Get ground calcium carbonate, add sodium carboxymethyl cellulose and make fine grained, add soybean isoflavone, shark cartilage micropowder, vitamin B
6, folic acid is evenly mixed, adds micropowder silica gel, magnesium stearate, and is evenly mixed.Measure the flowability of mixture, the uniformity of dosage units of mixture.Automatically loading capsule in the capsule machine.
Embodiment 2
Isoflavone content 43% soybean isoflavone, 0.5g
Shark cartilage micropowder 0.7g
Ground calcium carbonate 0.5g
Vitamin B
62mg
Folic acid 0.2mg
Micropowder silica gel 8mg
Magnesium stearate 5mg
Get ground calcium carbonate, add sodium carboxymethyl cellulose and make fine grained, add soybean isoflavone, shark cartilage micropowder, vitamin B
6, folic acid is evenly mixed, adds micropowder silica gel, magnesium stearate, and is evenly mixed.Measure the flowability of mixture, the uniformity of dosage units of mixture.Automatically loading capsule in the capsule machine.
Embodiment 3
Isoflavone content is 40% soybean isoflavone 0.25g
Shark cartilage micropowder 0.5g
Ground calcium carbonate 0.678g
Vitamin B
62mg
Folic acid 0.2mg
Micropowder silica gel 3mg
Magnesium stearate 3mg
Get ground calcium carbonate, add sodium carboxymethyl cellulose and make fine grained, add soybean isoflavone, shark cartilage micropowder, vitamin B
6, folic acid is evenly mixed, adds micropowder silica gel, magnesium stearate, and is evenly mixed.Measure the flowability of mixture, the uniformity of dosage units of mixture.Automatically loading capsule in the capsule machine.
Embodiment 4
Take by weighing raw material (daily dose) by following proportioning
Isoflavone content is 40% soybean isoflavone, 0.25g
Shark cartilage micropowder 0.5g
Ground calcium carbonate 0.339g
Precipitated calcium carbonate 0.339g
Vitamin B
62mg
Folic acid 0.2mg
Micropowder silica gel 2.5mg
Magnesium stearate 3mg
Take by weighing ground calcium carbonate and precipitated calcium carbonate, add sodium carboxymethyl cellulose and make fine grained, add soybean isoflavone, shark cartilage micropowder, vitamin B
6, folic acid is evenly mixed, adds micropowder silica gel, magnesium stearate, and is evenly mixed.Measure the flowability of mixture, the uniformity of dosage units of mixture.Automatically loading capsule in the capsule machine.
Claims (4)
1, the capsule preparations of a kind of bone density improving and deferring senility is characterized in that being made daily dose by the component of following weight proportion:
The soybean isoflavone of isoflavone content 35~43%, 0.15-0.5g
Shark cartilage micropowder 0.3-0.7g
Ground calcium carbonate 0.5-0.8g
Vitamin B
62mg
Folic acid 0.2mg
Micropowder silica gel 2-8mg
Magnesium stearate 1-5mg.
2, by the capsule preparations of described bone density improving of claim 1 and deferring senility, wherein the weight proportion of each component is:
Isoflavone content is 40% soybean isoflavone 0.25g
Shark cartilage micropowder 0.5g
Ground calcium carbonate 0.678g
Vitamin B
62mg
Folic acid 0.2mg
Micropowder silica gel 3mg
Magnesium stearate 3mg.
3, by the capsule preparations of described bone density improving of claim 1 and deferring senility, wherein the weight proportion of each component is:
Isoflavone content is 40% soybean isoflavone, 0.25g
Shark cartilage micropowder 0.5g
Ground calcium carbonate 0.339g
Precipitated calcium carbonate 0.339g
Vitamin B
62mg
Folic acid 0.2mg
Micropowder silica gel 2.5mg
Magnesium stearate 3mg.
4, according to the preparation method of the capsule preparations of claim 1 or 2 or 3 described bone density improving and deferring senility, it is characterized in that by following step:
Get ground calcium carbonate or take by weighing ground calcium carbonate and precipitated calcium carbonate, add sodium carboxymethyl cellulose and make fine grained, add soybean isoflavone, shark cartilage micropowder, vitamin B
6, folic acid is evenly mixed, adds micropowder silica gel, magnesium stearate, and is evenly mixed, measures the flowability of mixture, and the uniformity of dosage units of mixture is being loaded capsule in the capsule machine automatically.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510029989XA CN100496513C (en) | 2005-09-23 | 2005-09-23 | Bone density-increasing and senility-postponing capsule formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510029989XA CN100496513C (en) | 2005-09-23 | 2005-09-23 | Bone density-increasing and senility-postponing capsule formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1762386A true CN1762386A (en) | 2006-04-26 |
CN100496513C CN100496513C (en) | 2009-06-10 |
Family
ID=36746844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200510029989XA Expired - Fee Related CN100496513C (en) | 2005-09-23 | 2005-09-23 | Bone density-increasing and senility-postponing capsule formulation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100496513C (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1903220B (en) * | 2006-07-12 | 2011-07-06 | 江中药业股份有限公司 | Health-care food with function of improving skeletal density and its prepn. method |
CN105192701A (en) * | 2015-10-19 | 2015-12-30 | 宜都宏济科技有限公司 | Sturgeon compound preparation and preparation process thereof |
CN108478595A (en) * | 2018-05-01 | 2018-09-04 | 王康俊 | A kind of pharmaceutical composition containing calcium carbonate, vitamine D3, farnoquinone |
-
2005
- 2005-09-23 CN CNB200510029989XA patent/CN100496513C/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1903220B (en) * | 2006-07-12 | 2011-07-06 | 江中药业股份有限公司 | Health-care food with function of improving skeletal density and its prepn. method |
CN105192701A (en) * | 2015-10-19 | 2015-12-30 | 宜都宏济科技有限公司 | Sturgeon compound preparation and preparation process thereof |
CN108478595A (en) * | 2018-05-01 | 2018-09-04 | 王康俊 | A kind of pharmaceutical composition containing calcium carbonate, vitamine D3, farnoquinone |
CN108478595B (en) * | 2018-05-01 | 2021-07-02 | 海南施宝生物科技有限公司 | A pharmaceutical composition containing calcium carbonate, vitamin D3, and vitamin K2 |
Also Published As
Publication number | Publication date |
---|---|
CN100496513C (en) | 2009-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1193751C (en) | Therpauetic agent of osteoporisis comprising active ingredient of quercetin derivatives | |
CN102551045B (en) | Collagen calcium tablet | |
CN1875996A (en) | A composition having anti-oxygenation function | |
CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
CN101036691A (en) | Health-caring product for improving bone density and immunity | |
CN105079028A (en) | Health care product capable of improving bones and joints and preparation method of health care product | |
CN101049323A (en) | Health protection medicine in use for treating chronic degenerative diseases, and producing method | |
EP3117834B1 (en) | A bone and joint protection composition and use thereof | |
CN100496513C (en) | Bone density-increasing and senility-postponing capsule formulation | |
CN100349577C (en) | Radix scutellariae total flavone extract and use of Radix scutellaride glucoside in preparing medicine for treating osteoporosis | |
CN101028027A (en) | Chewing gum with breast-enlarging and beautifying functions | |
CN1421232A (en) | Nutritive health food with functions of reducing blood fat and delaying senility and its prepn process | |
CN1176602C (en) | Health food capable of increasing bone density and delaying senility and its production process | |
CN1109034C (en) | Composition of gambogic acid compounds with anticancer activity and its preparing process | |
CN1193750C (en) | Medicine for treating menopausal syndrome | |
CN109601880B (en) | Health food for increasing bone mineral density | |
CN1524447A (en) | Antioxidant compositions | |
CN112370430A (en) | Calcium and vitamin K2 tablet and preparation method thereof | |
CN1634130A (en) | Composition for preventing and treating women postmenopausal osteoporosis | |
CN1245407C (en) | Composition of garcinolic acid compounds, its preparing process and medical composition using it as active component | |
CN101091720A (en) | Health food with efficacy for preventing osteoporosis and preparation method | |
CN1823889A (en) | Soft capsule used for treating low sexual function and its preparation method | |
CN1559420A (en) | Medicne tablets with function of delaying senility, and prepn. method therefor | |
CN1264552C (en) | Preparation of preventing osteoporosis and delaying senility and its preparation process | |
CN1168278A (en) | Antineoplastic Chinese medicine prepn and its prepn process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090610 Termination date: 20140923 |
|
EXPY | Termination of patent right or utility model |